book a demo

-17th July 2014

Mirada Medical signs research collaboration agreement with RefleXion Medical to further development of biologically-guided Radiation Therapy

Multi-modality cancer imaging specialists Mirada Medical (Oxford UK) have teamed up with an emerging developer of radiation therapy equipment for fighting cancer, RefleXion Medical (Burlingame, CA), to evaluate the performance of RefleXion’s novel PET-guided radiotherapy system. The relationship will contribute to important feasibility studies and proof-of-principle simulations that explore the potential of RefleXion’s system with clinical PET and CT imaging datasets.

RefleXion Medical uniquely combines external beam radiation therapy with positron emission tomography (PET) imaging to deliver targeted radiation to one or multiple targets. Mirada Medical pioneered software for PET analysis in the early 2000’s and has been at the forefront of the movement to integrate PET imaging into radiation therapy planning. In working together, the companies expect to take the best of their respective technologies to deliver truly differential treatment modalities for cancer patients worldwide.

An initial study demonstrating the compatibility of RefleXion’s novel approach and state-of-the-art image registration techniques, using Mirada RTx, was recently completed and will be presented at AAPM 2014 in Austin, TX, during the ‘Joint Imaging – Therapy Scientific Session, Treatment Response Assessment’ on Thursday, July 24th.

Hugh Bettesworth, CEO of Mirada Medical said “Mirada has a very strong track record working with both PET imaging, and imaging for radiation treatment planning. I am very excited to have this opportunity to partner with RefleXion and help establish a truly innovative approach to cancer radiotherapy”.

Sam Mazin, President of RefleXion Medical said “We are committed to working closely with industry leaders such as Mirada Medical in building upon established multi-modality image registration technologies and to transition the field towards truly adaptive radiation therapy”.